医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Takeda Announces the Publication of Its Annual Report on Form 20-F for FY2018

2019年06月27日 PM09:00
このエントリーをはてなブックマークに追加


 

OSAKA, Japan

Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502/NYSE:TAK) hereby announces that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2019 (the “Annual Report”) with the U.S. Securities and Exchange Commission (the “SEC”). Takeda filed the Annual Report with the SEC on June 27, 2019, and the Annual Report can be accessed on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/.

In addition, Takeda will also provide a hard copy of the Annual Report, which includes its most recent complete audited financial statements free of charge to any shareholder upon request. Please contact Takeda Investor Relations by e-mail at takeda.ir.contact@takeda.com.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

For more information, visit https://www.takeda.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20190627005365/en/

CONTACT

Takeda Pharmaceutical Company

takeda.ir.contact@takeda.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作